Cell Pathways is testing drug it believes can prevent and treat certain cancers

Article Abstract:

Cell Pathways Inc. of Horsham, PA, has been keeping a low profile about its product due to pending patents. Now it is known to be testing its Prevatac, also known as exisulind, for treatment of a certain variation of colon cancer, recurring prostate cancer, and soon will test the drug on women with recurring breast cancer. The firm went public in November 1998. The drug seems to work in a way that is similar to arthritis drugs being tested by Monsanto and Merck; it also has a relationship to an enzyme that Viagra also interacts with, yet the two drugs have opposite effects on the enzyme.

Product information, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Anticancer Drugs, Research, Drugs, Product development, Pharmaceutical industry, Testing, Cancer research, Abstract, Growth, Antineoplastic agents, Cancer, Cancer cells, Cell Pathways Inc.

---

DuPont gets FDA clearance for AIDS drug

Article Abstract:

DuPont Co. has received approval from the Food and Drug Administration for a powerful new drug, Sustiva, to be used in the treatment of AIDS. Industry analysts, which have said that the drug is used to block viral replication, believe that Sustiva may earn $700 million or more in annual revenue for DuPont. Sustiva may become more popular among AIDS doctors and HIV-infected patients, compared with protese inhibitors from Merck and Glaxo Wellcome, because it is more potent and has a simpler dosing regimen.

Comment:

Has received approval from the FDA for a powerful new drug, Sustiva, to be used in the treatment of AIDS

Research and Development in the Physical, Engineering, and Life Sciences, Product introduction, New Products/Services, Viral Disease R&D, Viral research, E.I. du Pont de Nemours and Co., Article

---

Similar abstracts:

• Abstracts: Researchers say Hoechst drug may be treatment for cocaine, nicotine addicts. Healthy women can use cancer drug
• Abstracts: Goldman keeps it private even in going public. Goldman, with new card, plans a summer dance
• Abstracts: Tellabs is said to be near new deal for Ciena. BankAmerica president says he will quit; Nationsbank merger leads to culture clash
• Abstracts: The really real thing: Coke to peddle brand of purified bottled water in U.S. Fat-free snacks aren't wowing Frito customers
• Abstracts: Gillette to cut jobs by 11% as results lag. Tickle funny bones, and sell more Burger King Whoppers? Nothing toylike in Mattel chief's compensation

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.